[JURIST] The Securities and Exchange Commission (SEC) [official website] has filed an insider trading complaint [SEC release] against unknown investors in Martek Biosciences Corp. [corporate website], claiming that the investors purchased an unusually large number of call options in Martek in the two weeks preceding the December 21 announcement [DSM release] that DSM [corporate website] planned to purchase Martek. The SEC’s complaint, filed last week in the US District Court for the Southern District of New York [official website], alleges…